Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (PGNY) generates a steady flow of news as a global leader in women’s health and family building solutions listed on the Nasdaq Global Select Market. Company updates frequently focus on fertility and women’s health benefits, research on employee and member needs, and financial performance, giving investors and benefits professionals insight into how Progyny’s model is evolving.
News coverage commonly includes quarterly earnings results and financial guidance, which are also referenced in the company’s Form 8-K filings. These releases discuss revenue from fertility benefit services and pharmacy benefit services, member engagement trends, client additions, and key metrics such as assisted reproductive treatment cycles and utilization rates. Investors following PGNY news can see how changes in client count, covered lives, and engagement influence the company’s reported results and outlook.
Progyny also issues news about new programs and product expansions. For example, it has announced pregnancy, postpartum, and menopause programs for global employers that complement its existing global fertility and family building offering, along with details on features such as Global Care Advocates, knowledge centers, and country-specific navigator support. These announcements provide context on how Progyny is extending its reach across the women’s health continuum and into global markets.
Another important category of news involves research and thought leadership. Progyny has released studies on men’s fertility experiences and on gaps between employee expectations and employer offerings in women’s health benefits, conducted with Dynata. These stories highlight barriers such as stigma, cost, and benefit complexity, and they underscore the company’s focus on data-driven insights for employers.
Additional news items may cover conference participation, leadership recognition, and partnerships, such as appearances at healthcare conferences and recognition of the CEO as a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health. For anyone tracking PGNY, this news page offers a centralized view of operational, financial, and strategic developments over time.
Progyny (Nasdaq: PGNY) announced strong financial results for Q4 2022, expecting revenues and net income to be at the high end of previous guidance. The company anticipates operating cash flow of approximately $50 million for Q4 and $79 million for the full year. CEO Pete Anevski highlighted healthy client utilization and a robust client base of over 370 covering 5.4 million lives. Progyny will present at the JP Morgan Healthcare Conference on January 10, 2023. The company remains optimistic about client expansion and continued demand for fertility benefits in 2023.
Progyny (Nasdaq: PGNY) announced a resumption of Menopur deliveries, significantly impacting its financial guidance for Q4 and the full year 2022. The company projects revenue between $781.5 million to $786.5 million, indicating a 56%-57% growth, and net income of $28.5 million to $29.5 million. Q4 revenue is expected to be $208.9 million to $213.9 million, with a 64%-68% growth rate. Progyny serves over 370 clients covering 5.4 million members, anticipating historical dispensing patterns to return by end of 2022.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced its participation in the Credit Suisse 31st Annual Healthcare Conference. CEO Pete Anevski and CFO Mark Livingston will engage in a fireside chat on November 8, 2022, at 4:25 PM PT (7:25 PM ET). A live audiocast will be available on Progyny's website. The company is committed to enhancing family building benefits, providing patients with education and access to leading fertility specialists, ultimately reducing healthcare costs and improving clinical outcomes.
Progyny, Inc. (Nasdaq: PGNY) reported record quarterly revenue of $205.4 million, a 68% increase year-over-year, for the third quarter of 2022. The company secured a record 105 new client commitments, adding approximately 1.2 million covered lives. Adjusted EBITDA more than doubled to $35.0 million, reflecting strong demand for fertility solutions. However, net income decreased 21% to $13.2 million due to increased non-cash stock-based compensation. Full-year revenue guidance was raised to between $775 million and $785 million, indicating continued growth.
Progyny, Inc. (Nasdaq: PGNY) will report its financial results for Q3 2022 on November 3, 2022, after market close. A conference call will follow at 4:45 P.M. ET, accessible via dialing 1-866-825-7331 (U.S.) or 1-973-413-6106 (international) with passcode 265484. An audio replay will be available until November 10, 2022. Progyny specializes in fertility benefits management, aiming to improve patient outcomes and reduce employer costs. The company has received multiple accolades, including recognition from CNBC Disruptor 50 and Modern Healthcare.
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced that CEO Pete Anevski and CFO Mark Livingston will join a fireside chat at the BofA Securities 2022 Global Healthcare Conference on September 15, 2022, at 5:50 A.M. Eastern Time. This event aims to discuss Progyny's comprehensive fertility solutions which benefit employers, patients, and healthcare providers. Interested parties can access a live audiocast and replay on Progyny's website. The company has received multiple awards for its innovative approach to fertility benefits.
Progyny (Nasdaq: PGNY) announced the appointment of Lloyd Dean to its Board of Directors, effective August 30, 2022. Dean, the Chief Executive Emeritus of CommonSpirit Health, brings over 40 years of healthcare experience. Progyny's CEO, Pete Anevski, expressed confidence that Dean's expertise will enhance the company’s growth and leadership in fertility and family building benefits. Following this appointment, the Board now consists of ten members. Dean will serve on the Nominating and Corporate Governance Committee, focusing on expanding access to fertility solutions.
Progyny, Inc. (PGNY) reported record quarterly revenue of $195.0 million, reflecting a 52% growth from the prior year. Strong demand for fertility benefits led to a 37% increase in fertility services revenue, totaling $126.8 million, and an 87% surge in pharmacy services revenue, reaching $68.2 million. Despite a 53% decrease in net income, attributed to increased stock-based compensation, Adjusted EBITDA saw a 78% increase, reaching $32.9 million. The company raised its full-year guidance, projecting annual revenue between $750.0 million and $775.0 million.
Progyny's Clinical Outcomes Exceed National Benchmarks
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, has achieved superior clinical outcomes validated by Milliman, Inc. Its independent evaluation confirms Progyny’s methodology for measuring and publishing fertility treatment successes against national benchmarks. Since 2016, Progyny has consistently delivered faster pregnancies, fewer miscarriages, and healthier outcomes compared to national averages. The company emphasizes transparency and aims to raise standards in fertility benefits as it continues to expand its network of high-quality providers.
Progyny (PGNY) will release its financial results for Q2 2022 on August 4, 2022, after market close. An investor conference call is scheduled for 4:45 PM ET. Participants in the U.S. can join by dialing 1-866-825-7331, with international access via 1-973-413-6106, using passcode 265484. A replay will be available until August 11, 2022. Progyny, recognized for its comprehensive fertility benefits, aims to provide optimal clinical outcomes and reduce healthcare costs.